Conceptus Overview

Founded in 1992, Conceptus (CPTS) is engaged in the design, development and marketing of innovative medical products for use in the field of women's health.

Conceptus is currently focused on marketing its Essure® permanent birth control system worldwide. With the Essure product, Conceptus believes it has the technology to transform the field of permanent birth control, and is in the process of...More»

Founded in 1992, Conceptus (CPTS) is engaged in the design, development and marketing of innovative medical products for use in the field of women's health.

Conceptus is currently focused on marketing its Essure® permanent birth control system worldwide. With the Essure product, Conceptus believes it has the technology to transform the field of permanent birth control, and is in the process of marketing the Essure procedure globally.

The Essure procedure is the first and only non-incisional alternative to tubal ligation, which is the leading form of birth control worldwide.

The Essure procedure does not require incisions or general anesthesia. Essure can be performed in an outpatient setting, and women who have the procedure usually resume regular activities within 24-48 hours after the day of the procedure.

Headquartered in the United States, Conceptus has twice been awarded "Fastest Growing Business in Silicon Valley (California).

(NASDAQ: CPTS)«Less